Department of Nuclear Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Institute of Nuclear Medicine and Molecular Imaging of Zhejiang University, Key Laboratory of Medical Molecular Imaging of Zhejiang Province, Hangzhou 310009, China.
Amino Acids. 2013 Feb;44(2):673-81. doi: 10.1007/s00726-012-1391-y. Epub 2012 Sep 4.
A novel protein scaffold based on the cystine knot domain of the agouti-related protein (AgRP) has been used to engineer mutants that can bind to the α(v)β(3) integrin receptor with high affinity and specificity. In the current study, an (18)F-labeled AgRP mutant (7C) was prepared and evaluated as a positron emission tomography (PET) probe for imaging tumor angiogenesis. AgRP-7C was synthesized by solid phase peptide synthesis and site-specifically conjugated with 4-nitrophenyl 2-(18/19)F-fluoropropionate ((18/19)F-NFP) to produce the fluorinated peptide, (18/19)F-FP-AgRP-7C. Competition binding assays were used to measure the relative affinities of AgRP-7C and (19)F-FP-AgRP-7C to human glioblastoma U87MG cells that overexpress α(v)β(3) integrin. In addition, biodistribution, metabolic stability, and small animal PET imaging studies were conducted with (18)F-FP-AgRP-7C using U87MG tumor-bearing mice. Both AgRP-7C and (19)F-FP-AgRP-7C specifically competed with (125)I-echistatin for binding to U87MG cells with half maximal inhibitory concentration (IC(50)) values of 9.40 and 8.37 nM, respectively. Non-invasive small animal PET imaging revealed that (18)F-FP-AgRP-7C exhibited rapid and good tumor uptake (3.24 percentage injected dose per gram [% ID/g] at 0.5 h post injection [p.i.]). The probe was rapidly cleared from the blood and from most organs, resulting in excellent tumor-to-normal tissue contrasts. Tumor uptake and rapid clearance were further confirmed with biodistribution studies. Furthermore, co-injection of (18)F-FP-AgRP-7C with a large molar excess of blocking peptide c(RGDyK) significantly inhibited tumor uptake in U87MG xenograft models, demonstrating the integrin-targeting specificity of the probe. Metabolite assays showed that the probe had high stability, making it suitable for in vivo applications. (18)F-FP-AgRP-7C exhibits promising in vivo properties such as rapid tumor targeting, good tumor uptake, and excellent tumor-to-normal tissue ratios, and warrants further investigation as a novel PET probe for imaging tumor angiogenesis.
一种基于 agouti 相关蛋白(AgRP)半胱氨酸结结构域的新型蛋白支架已被用于设计能够与α(v)β(3)整联蛋白受体高亲和力和特异性结合的突变体。在本研究中,制备了一种(18)F 标记的 AgRP 突变体(7C),并将其作为正电子发射断层扫描(PET)探针用于成像肿瘤血管生成。AgRP-7C 通过固相肽合成合成,并通过位点特异性与 4-硝基苯基 2-(18/19)F-氟丙酸盐((18/19)F-NFP)缀合,生成氟化肽(18/19)F-FP-AgRP-7C。竞争结合实验用于测量 AgRP-7C 和(19)F-FP-AgRP-7C 与过表达α(v)β(3)整联蛋白的人胶质母细胞瘤 U87MG 细胞的相对亲和力。此外,使用 U87MG 荷瘤小鼠进行了(18)F-FP-AgRP-7C 的生物分布、代谢稳定性和小动物 PET 成像研究。AgRP-7C 和(19)F-FP-AgRP-7C 均可特异性与 U87MG 细胞结合,(125)I-echistatin 的半数最大抑制浓度(IC(50))值分别为 9.40 和 8.37 nM。非侵入性小动物 PET 成像显示,(18)F-FP-AgRP-7C 在 0.5 h 注射后具有快速良好的肿瘤摄取(3.24%注射剂量/克 [% ID/g])。探针从血液和大多数器官中迅速清除,导致良好的肿瘤与正常组织对比度。通过生物分布研究进一步证实了肿瘤摄取和快速清除。此外,在 U87MG 异种移植模型中,与大量过量的阻断肽 c(RGDyK)共注射(18)F-FP-AgRP-7C 可显著抑制肿瘤摄取,证明了探针的整联蛋白靶向特异性。代谢物测定表明,该探针具有很高的稳定性,适合体内应用。(18)F-FP-AgRP-7C 表现出有前途的体内特性,如快速肿瘤靶向、良好的肿瘤摄取和出色的肿瘤与正常组织比,有必要进一步研究作为一种新型 PET 探针用于成像肿瘤血管生成。